Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria
Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved..
Infections caused by multidrug resistant Gram-negative bacteria are becoming a worldwide problem due to their increasing incidence and associated high mortality. Carbapenem-resistant bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii are the most important in clinical practice. The objective of these guidelines is to update the recommendations for the diagnosis and treatment of infections caused by these multidrug resistant bacteria. Although 'old' antibiotics such as aminoglycosides, colistin, or tigecycline are frequently used for therapy of these bacteria, the 'new' beta-lactams such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam or cefiderocol are progressively becoming the first-line therapy for most of these microorganisms. The Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica) designated a panel of experts in the field to provide evidence-based recommendations in response to common clinical questions. This document is primarily focused on microbiological diagnosis, clinical management, and targeted antimicrobial therapy of these infections, with special attention to defining the role of the new antimicrobials in the treatment of these bacteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica (English ed.) - 41(2023), 6 vom: 19. Juni, Seite 360-370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pintado, Vicente [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.06.2023 Date Revised 28.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimce.2022.06.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350341982 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350341982 | ||
| 003 | DE-627 | ||
| 005 | 20231226044759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eimce.2022.06.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350341982 | ||
| 035 | |a (NLM)36522272 | ||
| 035 | |a (PII)S2529-993X(22)00281-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pintado, Vicente |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Infections caused by multidrug resistant Gram-negative bacteria are becoming a worldwide problem due to their increasing incidence and associated high mortality. Carbapenem-resistant bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii are the most important in clinical practice. The objective of these guidelines is to update the recommendations for the diagnosis and treatment of infections caused by these multidrug resistant bacteria. Although 'old' antibiotics such as aminoglycosides, colistin, or tigecycline are frequently used for therapy of these bacteria, the 'new' beta-lactams such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam or cefiderocol are progressively becoming the first-line therapy for most of these microorganisms. The Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica) designated a panel of experts in the field to provide evidence-based recommendations in response to common clinical questions. This document is primarily focused on microbiological diagnosis, clinical management, and targeted antimicrobial therapy of these infections, with special attention to defining the role of the new antimicrobials in the treatment of these bacteria | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acinetobacter baumannii | |
| 650 | 4 | |a Bacterias gramnegativas | |
| 650 | 4 | |a Carbapenem-resistant | |
| 650 | 4 | |a Carbapenemase-producing Enterobacterales | |
| 650 | 4 | |a Enterobacterales productores de carbapenemasa | |
| 650 | 4 | |a Gram-negative bacteria | |
| 650 | 4 | |a Multidrug resistant | |
| 650 | 4 | |a Multirresistentes | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a Resistentes a carbapenémicos | |
| 650 | 4 | |a Stenotrophomonas maltophilia | |
| 650 | 4 | |a Targeted antimicrobial therapy | |
| 650 | 4 | |a Terapia antibiótica dirigida | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Ruiz-Garbajosa, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilera-Alonso, David |e verfasserin |4 aut | |
| 700 | 1 | |a Baquero-Artigao, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Bou, Germán |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Grau, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Gutiérrez, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Larrosa, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a Machuca, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Martínez, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, María Milagro |e verfasserin |4 aut | |
| 700 | 1 | |a Morte-Romea, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Oliver, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Paño-Pardo, José Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Sorlí, Luisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica (English ed.) |d 2012 |g 41(2023), 6 vom: 19. Juni, Seite 360-370 |w (DE-627)NLM220666776 |x 2529-993X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:6 |g day:19 |g month:06 |g pages:360-370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimce.2022.06.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 6 |b 19 |c 06 |h 360-370 | ||